Genetically modified non-human animal with human or chimeric CLDN1
WO2025185668A8 Publication Date: 2025-10-02BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/080847
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-05
- Filing Date
- 2025-03-05
- Publication Date
- 2025-10-02
AI Technical Summary
Technical Problem
Traditional drug research and development methods using in vitro and in vivo animal models fail to replicate the complex biological environment of human diseases, leading to high failure rates and discrepancies between animal test results and clinical trials.
Method used
Development of genetically modified non-human animals with human or chimeric Claudin-1 (CLDN1) expression, which mimics human biological environments, allowing for more accurate drug screening and evaluation.
Benefits of technology
Enhances the efficiency and reduces the cost of drug development by providing a more reliable animal model that reflects human disease states and interactions, improving drug screening and evaluation accuracy.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to genetically modified non-human animals that express ahuman or humanized chimeric CLDN1, and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art